By accurately identifying those patients with FOXC1+ pro-metastatic cancer who are at greatest risk, such a test serves to refine and improve resource utilization, to optimize delivery of life-saving chemotherapy and targeted therapy to the patients who need it the most. Here, FOXC1 is linked to metastatic malignant neoplasm.